Ivermectin remains one of the most important antiparasitic drugs ever developed, credited with preventing blindness and disability in millions of people worldwide. But veterinary medicine has spent the past two decades documenting something that deserves calm, clear attention: parasites in livestock and household pets are losing susceptibility to this drug at a measurable rate. This article explains what the veterinary evidence actually shows, how resistance develops biologically, and what—if anything—it means for the ways ivermectin is used in people today.
A Remarkable Drug With Humble Origins
Ivermectin descends from avermectin, a compound isolated in the 1970s from Streptomyces avermitilis, a bacterium found in a soil sample collected in Japan. Researchers Satoshi Ōmura and William Campbell developed it into one of the most effective antiparasitic agents in history, work recognized with a share of the 2015 Nobel Prize in Physiology or Medicine. It is a fitting reminder that some of medicine's greatest tools have come not from a laboratory bench alone, but from careful observation of the ordinary, created world—a microorganism in the dirt, put to extraordinary use.
Ivermectin works by binding to glutamate-gated chloride channels found in the nerve and muscle cells of nematodes (roundworms) and certain arthropods, channels that do not exist in vertebrates in the same form. This binding causes sustained paralysis of the parasite's pharynx and body wall muscles, and the worm dies or is expelled. Because the drug also has some affinity for GABA-gated channels involved in a parasite's nervous system, it is broadly effective against a wide range of nematodes, plus mites and lice. Since the 1980s it has been used enormously in agriculture—in cattle, sheep, goats, horses, and swine—and in companion animals for heartworm prevention, as well as in humans for onchocerciasis (river blindness), strongyloidiasis, and scabies.
What Decades of Livestock Data Actually Show
The clearest, best-documented resistance has developed in Haemonchus contortus, the "barber pole worm" that infects the stomachs of sheep and goats worldwide. Because this parasite reproduces in enormous numbers and small ruminants have historically been dewormed frequently and often without confirming efficacy, resistance had ample opportunity to develop. Fecal egg count reduction tests—the standard method for measuring anthelmintic efficacy in the field—have repeatedly found that many sheep and goat operations in the United States, Australia, South America, and elsewhere no longer achieve the 95% reduction in egg counts that defines a fully effective treatment. In some herds, ivermectin efficacy has fallen well below that threshold, sometimes dramatically.
Resistance is not a single mechanism but usually several acting together:
- Target-site changes in the glutamate-gated chloride channel that reduce how well the drug binds.
- Increased drug efflux via P-glycoprotein, a cellular pump that many nematodes upregulate to expel ivermectin before it can act.
- Selection pressure from management practices—frequent dosing, underdosing relative to body weight, and treating entire herds rather than leaving a portion untreated (a practice called maintaining "refugia") that accelerates the spread of resistant genes through a parasite population.
This pattern is not unique to ivermectin; benzimidazole dewormers lost effectiveness against many of the same parasites decades earlier, for similar reasons. Veterinary parasitologists, including long-running research programs at the University of Georgia, now recommend rotating drug classes deliberately, confirming efficacy with regular fecal testing, and deliberately preserving some untreated parasite population to slow the spread of resistant genes—an approach grounded in the same logic that governs antibiotic stewardship in human medicine.
The Heartworm Warning Sign in Dogs
A second, more unsettling body of evidence involves Dirofilaria immitis, the heartworm parasite transmitted by mosquitoes to dogs. Since around 2005, veterinarians in the Mississippi Delta region reported cases in which dogs on properly dosed, monthly macrocyclic lactone prevention still became infected—so-called "lack of efficacy" reports, tracked by the American Heartworm Society. Genetic studies led by researchers including Catherine Bourguinat and Roger Prichard at McGill University identified specific single-nucleotide variants, particularly in P-glycoprotein-related genes, that were significantly more common in heartworm populations from dogs with confirmed breakthrough infections compared to susceptible reference strains. These findings, published in veterinary parasitology journals in the early 2010s, provided genetic, not just clinical, evidence that a resistant heartworm lineage had emerged in a specific U.S. region.
This matters because heartworm disease is serious and potentially fatal in dogs, and because it demonstrates that resistance to macrocyclic lactones is not confined to livestock gut parasites treated with pour-on or oral doses in a farmyard—it can also arise in a mosquito-borne filarial worm under sustained chemoprophylactic pressure, which is structurally more similar to the filarial parasites causing human onchocerciasis.
Does This Mean Human Parasites Are Becoming Resistant Too?
Here the evidence is far thinner, and it is important to be precise about what has and has not been shown. Ivermectin has been distributed for onchocerciasis control since 1987 through the Mectizan Donation Program, with well over a billion cumulative treatments given across Africa and parts of Latin America. Program evaluations have generally continued to show strong efficacy at the population level.
However, a notable study by Osei-Atweneboana and colleagues, published in The Lancet in 2007, examined communities in Ghana that had received more than a decade of repeated annual ivermectin treatment. The researchers found that microfilariae (the immature worm stage the drug targets) repopulated the skin more quickly after treatment in some of these communities than would be expected, suggesting a sub-optimal response. This was a clinical and epidemiological signal, not a confirmed genetic resistance mechanism—the authors themselves were careful to note that reduced response could reflect selection for less-susceptible parasites, but could also reflect other factors, such as differences in host immunity or worm biology across regions. Follow-up genetic work has looked for markers analogous to those found in resistant animal parasites, without producing the kind of definitive, reproducible finding that exists for heartworm or Haemonchus.
Separately, isolated case reports and small studies have described oral ivermectin treatment failures in crusted (Norwegian) scabies, a severe form of scabies infestation more common in immunocompromised or institutionalized patients. Some of these cases involved patients who had received multiple prior courses of the drug, and a small number of laboratory bioassays have found reduced susceptibility in mite populations taken from repeatedly treated patients. This is worth taking seriously as an early signal, but it remains a limited body of case-level evidence, not a demonstrated widespread resistance mechanism in human scabies mites.
Put plainly: veterinary resistance to ivermectin is well established, mechanistically understood, and geographically widespread. Human parasite resistance is, at most, an early and contested signal in a couple of specific contexts—repeated mass treatment for onchocerciasis and repeated dosing for crusted scabies. The two situations are not interchangeable, but the animal data offer a legitimate reason for continued vigilance rather than complacency.
Stewardship, Not Panic: What This Means for Patients and Families
None of this changes the fact that ivermectin, used as approved and directed by a physician, remains a safe and effective treatment for its approved human indications—onchocerciasis, strongyloidiasis, and scabies—when properly diagnosed and dosed. The lesson from veterinary medicine is not that the drug has failed, but that any antiparasitic loses effectiveness faster when it is used carelessly, repeatedly, or without confirming that it worked.
A few practical points follow from this for anyone caring for their own family's health:
- Ivermectin formulated for livestock is not the same product, concentration, or purity standard as ivermectin approved for human use, and the FDA has specifically warned against taking animal-labeled ivermectin products in people. This is a straightforward safety matter, not a matter of opinion.
- If a course of treatment for scabies, strongyloidiasis, or another parasitic condition does not resolve symptoms, that is worth reporting to your physician rather than simply repeating the same dose—treatment failure has several possible causes, and persistent or recurrent infestation deserves proper reevaluation.
- Families raising livestock or caring for dogs in heartworm-endemic regions should work with a veterinarian on confirmed dosing schedules and periodic efficacy testing rather than assuming any single product will always work as well as it once did.
The underlying principle is one worth holding onto in any area of medicine: a drug is a tool entrusted to us, and using it wisely—at the right dose, for the right diagnosis, under a treating clinician's guidance—is part of what it means to be a good steward of both the medicine and the body it is meant to help. Informed patients working closely with their own doctor, rather than reflexively deferring to broad institutional messaging or, conversely, self-treating without medical guidance, remain in the best position to make sound decisions for themselves and their families.
Key takeaway: Ivermectin resistance is well documented in livestock and heartworm parasites through solid genetic and field evidence, but in humans the signal remains limited and contested—making careful, physician-guided, non-repetitive use the wisest course rather than either alarm or complacency.